Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
X
publication

Microfluidic droplet enrichment for targeted sequencing.


Eastburn, D.J. et al.
Nucleic Acids Research (2015)
Abstract

Targeted sequence enrichment enables better identification of genetic variation by providing increased sequencing coverage for genomic regions of interest. Here, we report the development of a new target enrichment technology that is highly differentiated from other approaches currently in use. Our method, MESA (Microfluidic droplet Enrichment for Sequence Analysis), isolates genomic DNA fragments in microfluidic droplets and performs TaqMan PCR reactions to identify droplets containing a desired target sequence. The TaqMan positive droplets are subsequently recovered via dielectrophoretic sorting, and the TaqMan amplicons are removed enzymatically prior to sequencing. We demonstrated the utility of this approach by generating an average 31.6-fold sequence enrichment across 250 kb of targeted genomic DNA from five unique genomic loci. Significantly, this enrichment enabled a more comprehensive identification of genetic polymorphisms within the targeted loci. MESA requires low amounts of input DNA, minimal prior locus sequence information and enriches the target region without PCR bias or artifacts. These features make it well suited for the study of genetic variation in a number of research and diagnostic applications.



Authors

Eastburn, D.J., Huang, Y., Pellegrino, M., Sciambi, A., Ptáček, L.J., Abate, A.R.



VIEW

publication
Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms.
Taylor, J.
Blood (2020)
publication
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma.
Maia, C.
Blood (2020)
publication
Distinct genetic pathways define pre-leukemic and compensatory clonal hematopoiesis in Shwachman-Diamond syndrome
Kennedy, A. L.
BioRxiv (2020)
publication
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML.
Choe, S.
Blood Advances (2020)
REQUEST QUOTE